← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV18행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
hu3F8 (hu3F8)
Y-mAbs Therapeutics·Neuroblastoma
30 trials
Overview
Program
hu3F8
Overview
Company
Y-mAbs Therapeutics
Overview
Modality
CGT
Overview
Target
Neuroblastoma
Overview
Indication
Neuroblastoma; High-Risk
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Utilization of Neutrophil Elastase Tetrapeptide Substrate as a Linker Agent for Anti-GD2 Antibody Drug Conjugates.. Disialoganglioside GD2 (GD2) is highly expressed in several tumors. While anti-GD2 antibodies and GD2-based antibody-drug conjugates (ADCs) have shown some therapeutic efficacy, their activity requires enhancement. Elastase, abundant in tumor microenvironment, has substrates that can…
Toxicology
CRS
100%
Clinical
Safety signal
Utilization of Neutrophil Elastase Tetrapeptide Substrate as a Linker Agent for Anti-GD2 Antibody Drug Conjugates.. Disialoganglioside GD2 (GD2) is highly expressed in several tumors. While anti-GD2 antibodies and GD2-based antibody-drug conjugates (ADCs) have shown some therapeutic efficacy, their activity requires enhancement. Elastase, abundant in tumor microenvironment, has substrates that can…
Clinical
Selected reported efficacy
50%
Clinical
Result source
ClinicalTrials.gov NCT01857934
Clinical
Program phase
PHASE_1
Clinical
Trial ref
NCT01857934